UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00461U105

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 00461U105	13G	Page 2 of 8 Pages	

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	PERCEPTIVE A	Advisof	rs LLC	
2.	CHECK THE AP	PROPRIAT	TE BOX IF A GROUP*	(a) o (b) o
3.	SEC USE ONLY			
4.	CITIZENSHIP OI	R PLACE	OF ORGANIZATION	
Delaware, United States of America				
NUMBER OF 5. SOLE VOTING POWER		5.	SOLE VOTING POWER	0
	BENEFICIALLY OWNED BY 6. SHARED VOTING POWER		1,260,847	
RE	EACH PORTING	7.	SOLE DISPOSITIVE POWER	0
PERSON WITH: 8. SHARED DISPOSITIVE POWER		1,260,847		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		1,260,847	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		0	
11.	1. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		5.88%	
12.	12. Type of reporting person (See Instructions)		IA	

CUSIP No. 00461U105	13G	Page 3 of 8 Pages	

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			0
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		1,260,847	
PERSON WITH: 8. SHARED DISPOSITIVE POWER		1,260,847		
RE	EACH PORTING	7.	SOLE DISPOSITIVE POWER	0
	BENEFICIALLY OWNED BY 6. SHARED VOTING POWER		1,260,847	
NUMBER OF SHARES 5. SOLE VOTING POWER		0		
United States of America				
4.	CITIZENSHIP OF	R PLACE (DF ORGANIZATION	
3.	SEC USE ONLY			
2.	CHECK THE AP	PROPRIAT	E BOX IF A GROUP*	(a) o (b) o
	Joseph Edel	MAN		
1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			

	100		
CUSIP No. 00461U105	13G	Page 4 of 8 Pages	

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	Perceptive 1	Life Sci	ences Master Fund, Ltd.		
2.	CHECK THE AP	PROPRIAT	'E BOX IF A GROUP*	(a) o (b) o	
3.	SEC USE ONLY				
4. CITIZENSHIP OR PLACE OF ORGANIZATION CAYMAN ISLANDS					
-	MBER OF SHARES	5.	SOLE VOTING POWER	0	
BENEFICIALLY OWNED BY 6. SHARED VOTING POWER		6.	SHARED VOTING POWER	1,194,653	
RE	EACH PORTING	7.	SOLE DISPOSITIVE POWER	0	
PER	PERSON WITH: 8. SHARED DISPOSITIVE POWER		1,194,653		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		1,194,653		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		0		
11.	percent of class represented by amount in row (9)		5.57%		
12.	12. Type of reporting person (See Instructions)		СО		

C	CUSIP N	o. 00461U105	13G	Page 5 of 8 Pages	
Ite	em 1.				
	(a)	Name of Issuer:	Aclaris Therapeutics, Inc.		
	(b)	Address of Issuer's Principal Executiv	ve Offices: Suite 4	denwood Drive 00 n, PA 19355	
Ite	em 2.				
	(a)	Name of Person Filing:	Common Stock (as defined below) which are beneficially owned by P	") is being filed with respect to shares of of Aclaris Therapeutics, Inc. (the "Issuer") erceptive Advisors LLC, Joseph Edelman and und, Ltd. (together, the "Reporting Persons").	
	(b)	Address of Principal Business Office	or, if none, Residence:	51 Astor Place, 10 th Floor	
	(c)	Citizenship:	•	New York, NY 10003 Perceptive Advisors LLC is a Delaware limited liability company, Perceptive Life Sciences Master Fund, Ltd. is a Cayman Islands corporation and Joseph Edelman is a United States Citizen.	
	(d)	Title of Class of Securities:	Common Stock		
	(e)	CUSIP Number:	00461U105		
Ite	em 3.	If this statement is filed pursuant t	to §§240.13d-1(b) or 240.13d-2(b) or (c), check whe	her the person filing is a:	
	(a) (b) (c) (d) (e) (f) (g) (h) (i)	oBank as defined in sectionoInsurance company as definedoInvestment company regis⊠An investment adviser in aoAn employee benefit planoA parent holding companyoA savings associations as aoA church plan that is exclusiono1940 (15 U.S.C. 80a-3)		(1)(ii)(F); 1)(ii)(G); re Act (12 U.S.C. 1813);	
	(j)	o Group, in accordance with	1 §240.13d-1(b)(1)(ii)(J).		

CUSIP No. 00461U105 13G Page 6 of 8 Pages	
--	--

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned:	Perceptive Advisors LLC and Joseph Edelman beneficially own 1,260,847 shares of Common Stock, 1,194,653 of which are held by Perceptive Life Sciences Master Fund Ltd, a private investment fund (the "Fund") to which Perceptive Advisors LLC serves as the investment manager, and 66,194 of which are held in a trading account (the "Account") to which Perceptive Advisors LLC serves as the investment manager. Mr. Edelman is the managing member of Perceptive Advisors LLC.
(b)	Percent of class:	Perceptive Advisors LLC's and Joseph Edelman's beneficial ownership of 5.88%, and Perceptive Life Sciences Master Fund Ltd's beneficial ownership of 5.57%, is based on the sum of 21,432,907 outstanding shares of Common Stock of the Issuer as reflected on the Issuer's 10Q filed with the SEC on November 3, 2016.

(c) Number of shares as to which the person has: Perceptive Advisors LLC and Joseph Edelman

(i) (ii) (iii) (iv)	Sole power to vote or to direct the vote: Shared power to vote or to direct the vote: Sole power to dispose or to direct the disposition of: Shared power to dispose or to direct the disposition of:	0 1,260,847 0 1,260,847
Perceptive	Life Sciences Master Fund Ltd:	
(i)	Sole power to vote or to direct the vote:	0
(ii)	Shared power to vote or to direct the vote:	1,194,653
(iii)	Sole power to dispose or to direct the disposition of:	0
(iv)	Shared power to dispose or to direct the disposition of:	1,194,653

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

The Fund and the Account described in Item 4 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from, the sale of the securities held in its account. Filing of this statement by the Reporting Persons shall not be deemed an admission that they beneficially own the securities reported herein. The Reporting Persons expressly disclaim beneficial ownership of all securities reported herein.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Perceptive Advisors LLC:

(a) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Joseph Edelman:

(b) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Perceptive Life Sciences Master Fund Ltd:

(c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

<u>February 14, 2017</u> Date

PERCEPTIVE ADVISORS LLC

/s/ Joseph Edelman Signature

Joseph Edelman/Managing Member Name/Title

<u>February 14, 2017</u> Date

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

/s/ Joseph Edelman Signature

Joseph Edelman/Managing Member

February 14, 2017 Date

/s/ Joseph Edelman Signature

Joseph Edelman Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)